Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATFurniture, Fixtures and OtherLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

CytomX Therapeutics (CTMX) Accumulated Depreciation & Amortization (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Accumulated Depreciation & Amortization for 11 consecutive years, with $16.2 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Accumulated Depreciation & Amortization rose 10.51% year-over-year to $16.2 million, compared with a TTM value of $16.2 million through Dec 2024, up 10.51%, and an annual FY2024 reading of $16.2 million, up 10.51% over the prior year.
  • Accumulated Depreciation & Amortization was $16.2 million for Q4 2024 at CytomX Therapeutics, up from $14.7 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $16.2 million in Q4 2024 and bottomed at $11.4 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $14.1 million, with a median of $14.4 million recorded in 2022.
  • The sharpest move saw Accumulated Depreciation & Amortization grew 26.25% in 2020, then grew 2.19% in 2023.
  • Year by year, Accumulated Depreciation & Amortization stood at $11.4 million in 2020, then increased by 21.06% to $13.8 million in 2021, then rose by 3.91% to $14.4 million in 2022, then grew by 2.19% to $14.7 million in 2023, then grew by 10.51% to $16.2 million in 2024.
  • Business Quant data shows Accumulated Depreciation & Amortization for CTMX at $16.2 million in Q4 2024, $14.7 million in Q4 2023, and $14.4 million in Q4 2022.